Novel Injectable Pentablock Copolymer Based Thermoresponsive Hydrogels for Sustained Release Vaccines

AAPS Journal

Volumn 18, Issue 1, 2016, Pages 261-269

  Bobbala, Sharan ^a   Tamboli, Viral ^b   McDowell, Arlene ^a   Mitra, Ashim K ^b   Hook, Sarah ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

nanoparticles; pentablock copolymers; sustained release; thermoresponsive hydrogels; vaccine delivery

Indexed keywords

CANCER VACCINE; COPOLYMER; MACROGOL; NANOPARTICLE; POLYCAPROLACTONE; POLYLACTIDE; ANTIGEN; DELAYED RELEASE FORMULATION; HYDROGEL; IMMUNOLOGICAL ADJUVANT; MACROGOL DERIVATIVE; POLY(ETHYLENE GLYCOL)-POLY(CAPROLACTONE)-POLY(ETHYLENE GLYCOL); POLYESTER; POLYETHYLENE GLYCOL-POLYLACTIDE-POLYETHYLENE GLYCOL; POLYMER; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; GELATION; HUMORAL IMMUNITY; HYDROGEL; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; MOUSE; NONHUMAN; SUSTAINED DRUG RELEASE; TEMPERATURE; TRANSITION TEMPERATURE; VISCOSITY; ANIMAL; C57BL MOUSE; CELLULAR IMMUNITY; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; IMMUNOLOGY; MALE; MEDICINAL CHEMISTRY; MELANOMA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; CANCER VACCINES; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HYDROGELS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MALE; MELANOMA; MICE; MICE, INBRED C57BL; NANOPARTICLES; POLYESTERS; POLYETHYLENE GLYCOLS; POLYMERS; TEMPERATURE; VACCINES; VISCOSITY;

EID: 84952986510     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-015-9843-4     Document Type: Article

References (48)

1. Arnon R, Ben-Yedidia T. Old and new vaccine approaches. Int Immunopharmacol. 2003;3(8):1195–204.
2. Kersten GFA, Crommelin DJA. Liposomes and ISCOMs. Vaccine. 2003;21(9–10):915–20.
3. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev. 1997;156:199–209.
4. Myschik J, McBurney WT, Hennessy T, Phipps-Green A, Rades T, Hook S. Immunostimulatory biodegradable implants containing the adjuvant Quil-A-Part II: in vivo evaluation. J Drug Target. 2008;16(3):224–32.
5. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang X-F, et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat Med. 2013;19(4):465–72.
6. Gordon S, Teichmann E, Young K, Finnie K, Rades T, Hook S. In vitro and in vivo investigation of thermosensitive chitosan hydrogels containing silica nanoparticles for vaccine delivery. Eur J Pharm Sci. 2010;41(2):360–8.
7. Kamath AT, Mastelic B, Christensen D, Rochat AF, Agger EM, Pinschewer DD, et al. Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses. J Immunol. 2012;188(10):4828–37.
8. Foged C, Sundblad A, Hovgaard L. Targeting vaccines to dendritic cells. Pharm Res. 2002;19(3):229–38.
9. Gamvrellis A, Leong D, Hanley JC, Xiang SD, Mottram P, Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol. 2004;82(5):506–16.
10. Baldridge JR, Crane RT. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods. 1999;19(1):103–7.
11. Baldridge JR, McGowan P, Evans JT, Cluff C, Mossman S, Johnson D, et al. Taking a toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther. 2004;4(7):1129–38.
12. Kensil C, Wu J-Y, Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. In: Powell M, Newman M, editors. Vaccine design. Pharmaceutical biotechnology, vol. 6. US: Springer; 1995. p. 525–41.
13. Demana PH, Fehske C, White K, Rades T, Hook S. Effect of incorporation of the adjuvant Quil A on structure and immune stimulatory capacity of liposomes. Immunol Cell Biol. 2004;82(5):547–54.
14. Mikloska Z, Rückholdt M, Ghadiminejad I, Dunckley H, Denis M, Cunningham AL. Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-γ and IL-12 production. J Immunol. 2000;164(10):5167–76.
15. Rattanapak T, Young K, Rades T, Hook S. Comparative study of liposomes, transfersomes, ethosomes and cubosomes for transcutaneous immunisation: characterisation and in vitro skin penetration. J Pharm Pharmacol. 2012;64(11):1560–9.
16. Ruel-Gariepy E, Leroux JC. In situ-forming hydrogels—review of temperature-sensitive systems. Eur J Pharm Biopharm. 2004;58(2):409–26.
17. Jeong B, Kim SW, Bae YH. Thermosensitive sol–gel reversible hydrogels. Adv Drug Deliv Rev. 2002;54(1):37–51.
18. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res. 2006;23(12):2709–28.
19. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release. 2002;82(2–3):189–212.
20. Kojarunchitt T, Hook S, Rizwan S, Rades T, Baldursdottir S. Development and characterisation of modified poloxamer 407 thermoresponsive depot systems containing cubosomes. Int J Pharm. 2011;408(1–2):20–6.
21. Paavola A, Yliruusi J, Rosenberg P. Controlled release and dura mater permeability of lidocaine and ibuprofen from injectable poloxamer-based gels. J Control Release. 1998;52(1–2):169–78.
22. Liu Y, Zhu Y-Y, Wei G, Lu W-Y. Effect of carrageenan on poloxamer-based in situ gel for vaginal use: improved in vitro and in vivo sustained-release properties. Eur J Pharm Sci. 2009;37(3–4):306–12.
23. El-Kamel AH. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int J Pharm. 2002;241(1):47–55.
24. Gong C, Shi S, Dong P, Kan B, Gou M, Wang X, et al. Synthesis and characterization of PEG-PCL-PEG thermosensitive hydrogel. Int J Pharm. 2009;365(1–2):89–99.
25. Ma G, Miao B, Song C. Thermosensitive PCL-PEG-PCL hydrogels: synthesis, characterization, and delivery of proteins. J Appl Polym Sci. 2010;116(4):1985–93.
26. Gou M, Zheng L, Peng X, Men K, Zheng X, Zeng S, et al. Poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro. Int J Pharm. 2009;375(1–2):170–6.
27. Chen CC, Chueh JY, Tseng H, Huang HM, Lee SY. Preparation and characterization of biodegradable PLA polymeric blends. Biomaterials. 2003;24(7):1167–73.
28. Ge H, Hu Y, Yang S, Jiang X, Yang C. Preparation, characterization, and drug release behaviors of drug-loaded ε-caprolactone/L-lactide copolymer nanoparticles. J Appl Polym Sci. 2000;75(7):874–82.
29. Patel SP, Vaishya R, Mishra GP, Tamboli V, Pal D, Mitra AK. Tailor-made pentablock copolymer based formulation for sustained ocular delivery of protein therapeutics. J Drug Deliv. 2014;2014:401747. doi:10.1155/2014/401747.
30. Silva JM, Videira M, Gaspar R, Preat V, Florindo HF. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release. 2013;168(2):179–99.
31. Hamdy S, Haddadi A, Somayaji V, Ruan D, Samuel J. Pharmaceutical analysis of synthetic lipid A-based vaccine adjuvants in poly (D, L-lactic-co-glycolic acid) nanoparticle formulations. J Pharm Biomed. 2007;44(4):914–23.
32. Könnings S, Copland MJ, Davies NM, Rades T. A method for the incorporation of ovalbumin into immune stimulating complexes prepared by the hydration method. Int J Pharm. 2002;241(2):385–9.
33. Bobbala S, McDowell A, Hook S. Quantitation of the immunological adjuvants, monophosphoryl lipid A and Quil A in poly (lactic-co-glycolic acid) nanoparticles using high performance liquid chromatography with evaporative light scattering detection. J Chromatogr B. 2015;975:45–51.
34. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based a- and b-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol. 1998;76(1):34–40.
35. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell. 1994;76(1):17–27.
36. Kojarunchitt T, Baldursdottir S, Dong Y-D, Boyd BJ, Rades T, Hook S. Modified thermoresponsive poloxamer 407 and chitosan sol–gels as potential sustained-release vaccine delivery systems. Eur J Pharm Biopharm. 2015;89:74–81.
37. Filatenkov AA, Jacovetty EL, Fischer UB, Curtsinger JM, Mescher MF, Ingulli E. CD4 T cell-dependent conditioning of dendritic cells to produce IL-12 results in CD8-mediated graft rejection and avoidance of tolerance. J Immunol. 2005;174(11):6909–17.
38. McBurney WT, Lendemans DG, Myschik J, Hennessy T, Rades T, Hook S. In vivo activity of cationic immune stimulating complexes (PLUSCOMs). Vaccine. 2008;26(35):4549–56.
39. Charrueau C, Tuleu C, Astre V, Grossiord JL, Chaumeil JC. Poloxamer 407 as a thermogelling and adhesive polymer for rectal administration of short-chain fatty acids. Drug Dev Ind Pharm. 2001;27(4):351–7.
40. Mueller SN, Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A. 2009;106(21):8623–8.
41. Kim TS, Hufford MM, Sun J, Fu Y-X, Braciale TJ. Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. J Exp Med. 2010;207(6):1161–72.
42. Whitmire JK, Murali-Krishna K, Altman J, Ahmed R. Antiviral CD4 and CD8 T-cell memory: differences in the size of the response and activation requirements. Philos Trans R Soc Lond B Biol Sci. 2000;355(1395):373–9.
43. Highton AJ, Kojarunchitt T, Girardin A, Hook S, Kemp RA. Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma. Immunol Cell Biol. 2015;93(7):634–40.
44. Varypataki E, van der Maaden K, Bouwstra J, Ossendorp F, Jiskoot W. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity. AAPS J. 2015;17(1):216–26.
45. Joshi V, Geary S, Salem A. Biodegradable particles as vaccine delivery systems: size matters. AAPS J. 2013;15(1):85–94.
46. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12(8):557–69.
47. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer. 2004;4(5):401–11.
48. Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A. 2008;105(5):1650–5.